trial · primary record
Lenvatinib 20mg
Gastric Cancer
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 43 |
| Primary completion | 2027-08 |
| Primary endpoint | Major pathological response (MPR) rate |
| Registry ID | NCT04745988 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:43:30.609Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04745988
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.